BNTXBioNTech SE
$88.07-16% 1Y
$88.07
$83.8952 weeks$119.34
Is the business good?
Mixed
1 neutral, 3 without dataMargins steady. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Margin direction, 3 yearsStablederived
Margins have held roughly steady, a stable cost structure.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is BNTX?
BioNTech SE keeps −49% of every revenue dollar as operating profit, against −82% for the median Biotechnology name.
−49%
Operating margin · Biotechnology median −82% · fiscal year to FY2025
- Share count, year on year
- +0.54%
Share count, year on year · flat: no meaningful dilution
- R&D as % of revenue
- 73%
R&D as % of revenue
- Gross margin
- 78%
Gross margin
| Year | Operating margin |
|---|---|
| FY2020 | −17% |
| FY2021 | 81% |
| FY2022 | 73% |
| FY2023 | 18% |
| FY2024 | −48% |
| FY2025 | −49% |
Details›
- Gross marginfiscal year to FY2025
- 78%
- Operating marginfiscal year to FY2025
- −49%
- Net marginfiscal year to FY2025
- −40%
- Free cash flow margin
- 9.8%
- R&D as % of revenue
- 73%
- Revenue, trailing twelve months
- $2.87B
- Free cash flow, trailing twelve months
- $281M
- Net income, trailing twelve months
- −$1.14B
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.